Influenza;Influenza

Recenti Progressi in Medicina

Volumn 91, Issue 12, 2000, Pages 657-666

  Calza, Leonardo ^a,b   Briganti, Elisabetta ^a   Manfredi, Roberto ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Haemagglutinin; Influenza; Neuraminidase; Oseltamivir; Zanamivir

Indexed keywords

AMANTADINE; ANTIGEN; ANTIVIRUS AGENT; HEMAGGLUTININ; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

AGED; CLINICAL FEATURE; EPIDEMIC; GENETIC DRIFT; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORTALITY; REVIEW; TREATMENT PLANNING;

ACETAMIDES; AMANTADINE; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; GUANIDINES; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; INFLUENZA, HUMAN; ITALY; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PYRANS; SIALIC ACIDS; UNITED STATES; ZANAMIVIR;

EID: 0034533722     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Cox NJ. Prevention and control of influenza [Editorial]. Lancet 1999; 354 (suppl): siv30.
2. Pregliasco FE. Nuovi approcci terapeutici per l'influenza. In: Infettivologia '99 - Atti. Lecce, Italia, 1999: 241-6.
3. Ghendon Y. Influenza: its impact and control. World Health Statistics Quarterly 1992; 45: 306-11.
4. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354: 1277-82.
5. Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices. MMWR 1998; 47: RR-6.
6. Nicholson KG. Clinical features of influenza. Seminars in Respiratory Infections 1992; 7: 26-37.
7. Keech M, Scott AJ, Ryan PJJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilisation in a working population. Occup Med 1998; 48: 85-90.
8. Nicholson KG. Influenza. Curr Opin Infect Dis 1994; 7: 168-72.
9. Wiselka M. Influenza: diagnosis, management and prophylaxis. Br Med J 1994; 308: 1341-5.
10. Nicholson KG. Use of antivirals in influenza in the elderly: prophylaxis and therapy. Gerontology 1996; 42: 280-9.
11. Van Voris LP, Newell PM. Antivirals for the chemoprophylaxis and treatment of influenza. Seminars in Respiratory Infections 1992; 7: 61-70.
12. Potter CW. Influenza. In: Zuckerman AJ, Banatvala JR, Pattison JR, eds. Virologia clinica. Torino: Centro Scientifico Editore, 1994: 229-54.
13. Von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenzavirus replication. Nature 1993; 363: 418-23.
14. Bethell R, Smith P. Recent developments in sialidase inhibitors for the treatment of influenza. Drugs of the Future 1998; 23: 1099-109.
15. Von Itzstein M, Barry JG, Chong AKJ. The development of potent anti-influenza drugs. Curr Opin Thera Patients 1993; 3: 1755-62.
16. Bridges CB, Katz JM, Seto WH, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000; 181: 344-8.
17. Hampson AW. Surveillance for pandemic influenza. J Infect Dis 1997; 176 (suppl 1): S8-13.
18. Centers for Disease Control and Prevention. Influenza activity- United States, 1999-2000 season. MMWR 2000; 49: 173-7.
19. Silva ME, Cherry JD, Wilson RJ, Ghafouri NM, Bruckner DA. Acute fever and petecchial rash associated with influenza A virus infection. Clin Infect Dis 1999; 29: 453-4.
20. Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Katoh T, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998; 352: 873-5.
21. Barnett ED. Influenza immunization for children [Editorial]. N Engl J Med 1998; 338: 1459-61.
22. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148: 1094-102.
23. McMinn P, Carrello A, Cole C, Baker D, Hampson A. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community. Clin Infect Dis 1999; 29: 456-8.
24. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-24.
25. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994; 25: 123-31.
26. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanido-2,4 Dideoxy-2,3 Dehydro-N-Acetylneuraminic Acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9.
27. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-Guanidino-2,4 Dideoxy-2,3 Dehydro-N-Acetylneuraminic acid) is a potent inhibitor of influenza virus inferrets. Antimicrob Agents Chemother 1995; 39: 2583-4.
28. Dines GD, Bethall R, Daniel M. Preclinical development of low toxicity drugs. Drug Safety 1998; 19: 233-41.
29. Cass LMR, Efthymiopoulus C, Bye A. Review of the pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal dosing in healty volunteers. Clinical Pharmacokinetics 1999; 36 (suppl 1): 1-11.
30. Cass LMR, Brown J, Fickford J, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healty volunteers. Clinical Pharmacokinetics 1999; 36 (suppl 1): 21-31.
31. Cass LMR, Efthymiopoulus C, Bye A. Effect of renal impairment on the pharmacokinetics of zanamivir. Clinical Pharmacokinetics 1999; 36 (suppl 1): 13-9.
32. Webster A, Boyce M, Edmundson S, Miller I. Co-administration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversly affect the production of anti-haemagglutinin antibodies (HAI titre) in healty volunteers. Clinical Pharmacokinetics 1999; 36 (Suppl 1): 51-8.
33. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med 1997; 337: 874-80.
34. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
35. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor, zanamivir, in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40: 42-8.
36. The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81.
37. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180: 586-93.
38. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997: 230.
39. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, 1998: 11.
40. Hayden FG, Atmar RI, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43.
41. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35.
42. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999; 58: 851-60.
43. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Neuraminidase Study Group. JAMA 2000; 283: 1016-24.
44. Grotto I, Mandel Y, Green MS, et al. Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 1998; 26: 913-7.
45. Gavaert TM, Thijs CT. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-5.
46. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-93 and 1993-94 influenza vaccines. N Engl J Med 1998; 339: 1797-802.
47. Ropper AH, Victor M. Influenza vaccination and the Guillain-Barré syndrome [Editorial]. N Engl J Med 1998; 339: 1845-6.
48. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338: 1405-12.